Quarterly report · Q2
2934.TEDINET S100PYFW
Period2022-06-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.1bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.9bn | 2021-06-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | −¥368m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥264m | 2021-06-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | −¥382m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥713m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥238m | 2021-06-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥382m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥238m | 2021-06-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥349m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥156m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥308m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥156m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥7.8bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥5.5bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.6bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.2bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.3bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥594m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥288m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥800m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥77m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-76.45 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-47.82 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.31 | 2021-06-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.01 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.33 | 2021-06-01 → 2021-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 50.9% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 31
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥277m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥55m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥266m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥181,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥412m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | −¥91m |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2021-11-30 | −¥195m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥552m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥552m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥64m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥1.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥1.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥391m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2021-11-30 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2021-11-30 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2021-11-30 | ¥459m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 489
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)監査法人アヴァンティア | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)相 馬 裕 晃 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)橋 本 剛 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 3912686000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 9103908000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 11876681000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 237648000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -381998000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 712818000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 155731000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -349434000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 400519000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 155731000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | -307955000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 400457000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 4333576000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 4162053000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 4156784000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 5489212000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 7785601000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 6060538000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 36.31 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -76.45 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 90.64 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 34.33 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 86.68 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.789 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.509 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.682 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | -288169000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | -593755000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | -366943000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -77102000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -800326000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -860094000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | 2838527000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | 1266010000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 2564597000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 4104351000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 2840582000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 2968654000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 19.01 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -47.82 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4851024 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4871024 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4851024 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4871024 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |